Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available.
On January 28, 2025, Calidi Biotherapeutics announced the termination of its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, effective January 23, 2025. The decision followed a successful fundraising effort that bolstered its cash position to $9.6 million as of December 31, 2024, allowing the company to focus on its clinical and operational goals without the SEPA framework. This strategic move reflects Calidi’s commitment to enhancing shareholder value and advancing its leadership in targeted antitumor virotherapies, with recent progress including an IND clearance by the FDA and new funding from public offerings.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California. It specializes in developing innovative stem cell-based platforms that utilize oncolytic viruses to target high-grade gliomas and solid tumors, aiming to enhance efficacy and safety.
YTD Price Performance: -44.07%
Average Trading Volume: 1,839,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.22M
See more data about CLDI stock on TipRanks’ Stock Analysis page.
